US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
US5433081A
(en)
*
|
1993-01-22 |
1995-07-18 |
Major; Thomas O. |
Refrigerant recovery and purification method and apparatus with oil adsorbent separator
|
JP3484197B2
(ja)
|
1993-09-03 |
2004-01-06 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
アミン誘導化ヌクレオシドおよびオリゴヌクレオシド
|
US5502177A
(en)
*
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
JP4053595B2
(ja)
*
|
1995-09-22 |
2008-02-27 |
メディカル・リサーチ・カウンシル |
核酸の突然変異誘発におけるまたはそれに関する改良
|
US5854033A
(en)
|
1995-11-21 |
1998-12-29 |
Yale University |
Rolling circle replication reporter systems
|
US20040033973A1
(en)
*
|
2002-08-16 |
2004-02-19 |
Muthiah Manoharan |
Compounds and oligomeric compounds comprising novel nucleobases
|
US7812149B2
(en)
*
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US20040171031A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
US20050053976A1
(en)
*
|
1996-06-06 |
2005-03-10 |
Baker Brenda F. |
Chimeric oligomeric compounds and their use in gene modulation
|
WO2005121368A1
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Chimeric gapped oligomeric compositions
|
US20050119470A1
(en)
*
|
1996-06-06 |
2005-06-02 |
Muthiah Manoharan |
Conjugated oligomeric compounds and their use in gene modulation
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
US6111085A
(en)
*
|
1996-09-13 |
2000-08-29 |
Isis Pharmaceuticals, Inc. |
Carbamate-derivatized nucleosides and oligonucleosides
|
USRE44779E1
(en)
|
1997-03-07 |
2014-02-25 |
Santaris Pharma A/S |
Bicyclonucleoside and oligonucleotide analogues
|
US6617422B1
(en)
|
1997-05-23 |
2003-09-09 |
Peter Nielsen |
Peptide nucleic acid monomers and oligomers
|
JP2002510319A
(ja)
|
1997-07-01 |
2002-04-02 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
US6028183A
(en)
|
1997-11-07 |
2000-02-22 |
Gilead Sciences, Inc. |
Pyrimidine derivatives and oligonucleotides containing same
|
CA2309340C
(en)
*
|
1997-11-07 |
2006-02-21 |
Isis Pharmaceuticals Inc. |
Pyrimidine derivatives for labeled binding partners
|
US6007992A
(en)
*
|
1997-11-10 |
1999-12-28 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
US20040186071A1
(en)
*
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
US7321828B2
(en)
*
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
WO1999060167A1
(en)
*
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
EP1469009A2
(de)
*
|
1998-05-21 |
2004-10-20 |
Isis Parmaceuticals, Inc. |
Zusammensetzungen und Verfahren für nicht-parenterale Verabreichung von Oligonukleotiden
|
CA2336384A1
(en)
*
|
1998-07-02 |
2000-01-13 |
The Trustees Of Columbia University In The City Of New York |
Oligonucleotide inhibitors of bcl-xl
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6225293B1
(en)
|
1998-09-02 |
2001-05-01 |
Isis Pharmaceuticals, Inc. |
Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6300320B1
(en)
|
1999-01-05 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Modulation of c-jun using inhibitors of protein kinase C
|
US6127124A
(en)
*
|
1999-01-20 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
Fluorescence based nuclease assay
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6147200A
(en)
*
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
US6727356B1
(en)
|
1999-12-08 |
2004-04-27 |
Epoch Pharmaceuticals, Inc. |
Fluorescent quenching detection reagents and methods
|
US20040081959A9
(en)
*
|
1999-12-08 |
2004-04-29 |
Epoch Biosciences, Inc. |
Fluorescent quenching detection reagents and methods
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US20060166227A1
(en)
*
|
2000-06-20 |
2006-07-27 |
Stephen Kingsmore |
Protein expression profiling
|
US6323009B1
(en)
*
|
2000-06-28 |
2001-11-27 |
Molecular Staging, Inc. |
Multiply-primed amplification of nucleic acid sequences
|
US8568766B2
(en)
*
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
JP5305553B2
(ja)
|
2000-10-12 |
2013-10-02 |
ユニバーシティー オブ ロチェスター |
癌細胞の増殖を阻害する組成物
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US20040121313A1
(en)
*
|
2002-12-06 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of bioagents in organs for transplantation
|
US7226739B2
(en)
|
2001-03-02 |
2007-06-05 |
Isis Pharmaceuticals, Inc |
Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
|
US20040121314A1
(en)
*
|
2002-12-06 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of bioagents in containers
|
US20030027135A1
(en)
*
|
2001-03-02 |
2003-02-06 |
Ecker David J. |
Method for rapid detection and identification of bioagents
|
US20040121310A1
(en)
*
|
2002-12-18 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of bioagents in forensic studies
|
US7718354B2
(en)
*
|
2001-03-02 |
2010-05-18 |
Ibis Biosciences, Inc. |
Methods for rapid identification of pathogens in humans and animals
|
US7666588B2
(en)
*
|
2001-03-02 |
2010-02-23 |
Ibis Biosciences, Inc. |
Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
|
CA2441071C
(en)
|
2001-03-14 |
2010-06-22 |
Myriad Genetics, Inc. |
Tsg101-gag interaction and use thereof
|
CA2633171C
(en)
|
2001-06-20 |
2012-11-20 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2790034A1
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US7217510B2
(en)
*
|
2001-06-26 |
2007-05-15 |
Isis Pharmaceuticals, Inc. |
Methods for providing bacterial bioagent characterizing information
|
US8073627B2
(en)
|
2001-06-26 |
2011-12-06 |
Ibis Biosciences, Inc. |
System for indentification of pathogens
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
NZ573831A
(en)
|
2001-09-18 |
2010-07-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
|
US7070933B2
(en)
*
|
2001-09-28 |
2006-07-04 |
Gen-Probe Incorporated |
Inversion probes
|
NZ566396A
(en)
|
2001-10-09 |
2009-07-31 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
NZ533933A
(en)
|
2002-01-02 |
2008-06-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of glioma tumor
|
US7553619B2
(en)
*
|
2002-02-08 |
2009-06-30 |
Qiagen Gmbh |
Detection method using dissociated rolling circle amplification
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
WO2003100035A2
(en)
*
|
2002-04-01 |
2003-12-04 |
Isis Pharmaceuticals, Inc. |
Method for rapid detection and identification of viral bioagents
|
US7169916B2
(en)
*
|
2002-04-01 |
2007-01-30 |
Isis Pharmaceuticals, Inc. |
Chloral-free DCA in oligonucleotide synthesis
|
CA2481507A1
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
US20040092470A1
(en)
*
|
2002-06-18 |
2004-05-13 |
Leonard Sherry A. |
Dry powder oligonucleotide formualtion, preparation and its uses
|
AU2003257181A1
(en)
|
2002-08-05 |
2004-02-23 |
University Of Rochester |
Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
|
JP2006500030A
(ja)
*
|
2002-09-20 |
2006-01-05 |
イェール ユニバーシティ |
リボスイッチ、その使用方法、ならびにリボスイッチとともに用いるための組成物
|
WO2004026804A1
(en)
*
|
2002-09-20 |
2004-04-01 |
Integrated Dna Technologies, Inc. |
Anthraquinone quencher dyes, their methods of preparation and use
|
US7229976B2
(en)
|
2002-09-26 |
2007-06-12 |
Isis Pharmaceuticals, Inc. |
Modulation of forkhead box O1A expression
|
WO2004110345A2
(en)
*
|
2002-10-29 |
2004-12-23 |
Pharmacia Corporation |
Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
|
US9150606B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
CA2504720C
(en)
|
2002-11-05 |
2013-12-24 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
WO2004044132A2
(en)
*
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
DK2336318T3
(da)
|
2002-11-13 |
2013-07-15 |
Genzyme Corp |
Antisense-modulering af apolipoprotein b-ekspression
|
EP1569695B1
(de)
|
2002-11-13 |
2013-05-15 |
Genzyme Corporation |
Antisense-modulation von apolipoprotein-b-expression
|
JP4555089B2
(ja)
*
|
2002-11-15 |
2010-09-29 |
モーフオテク・インコーポレーテツド |
invitro免疫感作により創製されたハイブリドーマからの抗体の高生産量の生成方法
|
US8007804B2
(en)
|
2002-11-15 |
2011-08-30 |
Musc Foundation For Research Development |
Complement receptor 2 targeted complement modulators
|
AU2003294462C1
(en)
|
2002-11-21 |
2011-06-30 |
University Of Utah Research Foundation |
Purinergic modulation of smell
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
JP2006516193A
(ja)
|
2002-12-06 |
2006-06-29 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
ヒトおよび動物における病原体の迅速な同定方法
|
US20040121312A1
(en)
*
|
2002-12-18 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of the absence of bioagents
|
US20040122857A1
(en)
*
|
2002-12-18 |
2004-06-24 |
Ecker David J. |
Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in forensic studies thereby
|
US20040121315A1
(en)
*
|
2002-12-18 |
2004-06-24 |
Ecker David J. |
Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in containers thereby
|
US9487823B2
(en)
*
|
2002-12-20 |
2016-11-08 |
Qiagen Gmbh |
Nucleic acid amplification
|
WO2004058987A2
(en)
|
2002-12-20 |
2004-07-15 |
Qiagen Gmbh |
Nucleic acid amplification
|
US6977153B2
(en)
*
|
2002-12-31 |
2005-12-20 |
Qiagen Gmbh |
Rolling circle amplification of RNA
|
DK1597366T3
(da)
|
2003-02-11 |
2013-02-25 |
Antisense Therapeutics Ltd |
Modulering af ekspression af insulin-lignende vækstfaktor receptor I
|
US7002006B2
(en)
*
|
2003-02-12 |
2006-02-21 |
Isis Pharmaceuticals, Inc. |
Protection of nucleosides
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US8043834B2
(en)
|
2003-03-31 |
2011-10-25 |
Qiagen Gmbh |
Universal reagents for rolling circle amplification and methods of use
|
US20040198640A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Dharmacon, Inc. |
Stabilized polynucleotides for use in RNA interference
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US8046171B2
(en)
*
|
2003-04-18 |
2011-10-25 |
Ibis Biosciences, Inc. |
Methods and apparatus for genetic evaluation
|
US8057993B2
(en)
|
2003-04-26 |
2011-11-15 |
Ibis Biosciences, Inc. |
Methods for identification of coronaviruses
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US8158354B2
(en)
|
2003-05-13 |
2012-04-17 |
Ibis Biosciences, Inc. |
Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
|
US7964343B2
(en)
*
|
2003-05-13 |
2011-06-21 |
Ibis Biosciences, Inc. |
Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
|
WO2004108081A2
(en)
*
|
2003-06-02 |
2004-12-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide synthesis with alternative solvents
|
AU2004253455B2
(en)
|
2003-06-03 |
2011-03-03 |
Eli Lilly And Company |
Modulation of survivin expression
|
EP3604537B1
(de)
|
2003-06-13 |
2021-12-08 |
Alnylam Europe AG |
Doppelsträngige ribonukleinsäure mit erhöhter wirksamkeit in einem organismus
|
EP1636342A4
(de)
*
|
2003-06-20 |
2008-10-08 |
Isis Pharmaceuticals Inc |
Oligomere verbindungen zur verwendung bei der modulation von genen
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
AU2004268614C1
(en)
|
2003-08-27 |
2010-10-28 |
Ophthotech Corporation |
Combination therapy for the treatment of ocular neovascular disorders
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
US20080138808A1
(en)
*
|
2003-09-11 |
2008-06-12 |
Hall Thomas A |
Methods for identification of sepsis-causing bacteria
|
US8097416B2
(en)
|
2003-09-11 |
2012-01-17 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
US7956175B2
(en)
|
2003-09-11 |
2011-06-07 |
Ibis Biosciences, Inc. |
Compositions for use in identification of bacteria
|
US20100035239A1
(en)
*
|
2003-09-11 |
2010-02-11 |
Isis Pharmaceuticals, Inc. |
Compositions for use in identification of bacteria
|
US20060240412A1
(en)
*
|
2003-09-11 |
2006-10-26 |
Hall Thomas A |
Compositions for use in identification of adenoviruses
|
US8546082B2
(en)
|
2003-09-11 |
2013-10-01 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
AU2004274021B2
(en)
*
|
2003-09-18 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
4'-thionucleosides and oligomeric compounds
|
AR045937A1
(es)
|
2003-09-18 |
2005-11-16 |
Lilly Co Eli |
Modulacion de la expresion del factor de iniciacion eucariotico eif4e
|
JP2007507430A
(ja)
|
2003-10-10 |
2007-03-29 |
メディテック リサーチ リミテッド |
疾患の治療におけるヒアルロナン合成および分解の調節法
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
WO2005049849A2
(en)
|
2003-11-14 |
2005-06-02 |
Integrated Dna Technologies, Inc. |
Fluorescence quenching azo dyes, their methods of preparation and use
|
PT2161283E
(pt)
|
2003-11-17 |
2014-08-29 |
Genentech Inc |
Composições que compreendem anticorpos contra cd79b conjugados a um agente de inibição do crescimento ou agente citotóxico e métodos para o tratamento de tumor de origem hematopoiética
|
EP1711606A2
(de)
|
2004-01-20 |
2006-10-18 |
Isis Pharmaceuticals, Inc. |
Modulation der expression des glucocorticoidrezeptors
|
US8778900B2
(en)
*
|
2004-01-22 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP1 expression
|
US7468431B2
(en)
*
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
WO2005078094A2
(en)
*
|
2004-02-06 |
2005-08-25 |
Dharmacon, Inc. |
Stabilized rnas as transfection controls and silencing reagents
|
US20090280567A1
(en)
*
|
2004-02-06 |
2009-11-12 |
Dharmacon, Inc. |
Stabilized sirnas as transfection controls and silencing reagents
|
US7666592B2
(en)
*
|
2004-02-18 |
2010-02-23 |
Ibis Biosciences, Inc. |
Methods for concurrent identification and quantification of an unknown bioagent
|
US8119336B2
(en)
|
2004-03-03 |
2012-02-21 |
Ibis Biosciences, Inc. |
Compositions for use in identification of alphaviruses
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP2700720A3
(de)
|
2004-03-15 |
2015-01-28 |
Isis Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Optimierung der Spaltung von RNA durch RNase H
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
WO2005097817A2
(en)
|
2004-04-05 |
2005-10-20 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
US20050260755A1
(en)
*
|
2004-04-06 |
2005-11-24 |
Isis Pharmaceuticals, Inc. |
Sequential delivery of oligomeric compounds
|
JP4584987B2
(ja)
|
2004-04-30 |
2010-11-24 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
C5修飾ピリミジンを含むオリゴヌクレオチド
|
AU2005326817B2
(en)
|
2004-05-21 |
2012-04-19 |
Benaroya Research Institute |
Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
|
CA2567839C
(en)
*
|
2004-05-24 |
2011-06-28 |
Isis Pharmaceuticals, Inc. |
Mass spectrometry with selective ion filtration by digital thresholding
|
US20050266411A1
(en)
*
|
2004-05-25 |
2005-12-01 |
Hofstadler Steven A |
Methods for rapid forensic analysis of mitochondrial DNA
|
AU2005252663B2
(en)
*
|
2004-06-03 |
2011-07-07 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
US8394947B2
(en)
*
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7811753B2
(en)
|
2004-07-14 |
2010-10-12 |
Ibis Biosciences, Inc. |
Methods for repairing degraded DNA
|
US7427675B2
(en)
|
2004-08-23 |
2008-09-23 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
WO2006135400A2
(en)
|
2004-08-24 |
2006-12-21 |
Isis Pharmaceuticals, Inc. |
Methods for rapid identification of recombinant organisms
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
DK1809303T3
(da)
|
2004-09-23 |
2019-06-11 |
Arc Medical Devices Inc |
Farmaceutisk sammensætning og metoder i relation til hæmning af fibrøs adhæsion eller inflammatoriske lidelser ved brug af lavsulfat-fucan
|
US7923206B2
(en)
*
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Method of determining a cellular response to a biological agent
|
US7935811B2
(en)
*
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
US8084207B2
(en)
*
|
2005-03-03 |
2011-12-27 |
Ibis Bioscience, Inc. |
Compositions for use in identification of papillomavirus
|
US8182992B2
(en)
|
2005-03-03 |
2012-05-22 |
Ibis Biosciences, Inc. |
Compositions for use in identification of adventitious viruses
|
AU2006223498A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
US7476733B2
(en)
*
|
2005-03-25 |
2009-01-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
|
US20060223777A1
(en)
*
|
2005-03-29 |
2006-10-05 |
Dharmacon, Inc. |
Highly functional short hairpin RNA
|
EP1863908B1
(de)
*
|
2005-04-01 |
2010-11-17 |
Qiagen GmbH |
Reverse transkription und amplifikation von rna bei simultaner degradierung von dna
|
AU2006251637B2
(en)
*
|
2005-05-20 |
2012-06-14 |
Integrated Dna Technologies, Inc. |
Compounds and methods for labeling oligonucleotides
|
US9505867B2
(en)
|
2005-05-31 |
2016-11-29 |
Ecole Polytechmique Fédérale De Lausanne |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
US8252756B2
(en)
|
2005-06-14 |
2012-08-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
AU2006272776B2
(en)
*
|
2005-07-21 |
2012-01-19 |
Ibis Biosciences, Inc. |
Methods for rapid identification and quantitation of nucleic acid variants
|
US7776532B2
(en)
|
2005-08-11 |
2010-08-17 |
Synthetic Genomics, Inc. |
Method for in vitro recombination
|
CA2617693A1
(en)
|
2005-08-17 |
2007-02-22 |
Medexis S.A. |
Composition and method for determination of ck19 expression
|
JP5523705B2
(ja)
|
2005-08-29 |
2014-06-18 |
レグルス・セラピューティクス・インコーポレイテッド |
Mir−122aをモジュレートする使用方法
|
DE102005042073B4
(de)
*
|
2005-08-31 |
2010-11-11 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Faserlaser
|
EP1762627A1
(de)
|
2005-09-09 |
2007-03-14 |
Qiagen GmbH |
Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
|
CA2623772A1
(en)
|
2005-09-19 |
2007-03-29 |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Modulation of glucocorticoid receptor expression
|
EP1937813A2
(de)
|
2005-09-19 |
2008-07-02 |
Isis Pharmaceuticals, Inc. |
Modulation der expression des glucagonrezeptors
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
EP2402435A3
(de)
|
2005-10-14 |
2012-03-28 |
MUSC Foundation For Research Development |
Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
|
EP2325315B1
(de)
|
2005-10-28 |
2014-05-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression des Huntingtin-Gens
|
CA2626690A1
(en)
|
2005-11-09 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
US7807652B2
(en)
|
2005-11-21 |
2010-10-05 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US8313901B2
(en)
*
|
2005-12-21 |
2012-11-20 |
Yale University |
Methods and compositions related to the modulation of riboswitches
|
EP1976567B1
(de)
|
2005-12-28 |
2020-05-13 |
The Scripps Research Institute |
Natürliche antisense- und nicht-kodierende rna-transkripte als arzneitargets
|
DK2314594T3
(da)
|
2006-01-27 |
2014-10-27 |
Isis Pharmaceuticals Inc |
6-modificerede bicykliske nukleinsyreanaloger
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
CA2640058C
(en)
|
2006-01-27 |
2018-04-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of micrornas
|
ES2544861T3
(es)
|
2006-03-31 |
2015-09-04 |
Alnylam Pharmaceuticals Inc. |
Composiciones y métodos para inhibir la expresión del gen Eg5
|
MX2008014005A
(es)
*
|
2006-05-03 |
2009-01-27 |
Baltic Technology Dev Ltd |
Agentes antisentido que combinan un oligonucleotido modificado con base fuertemente unida y nucleasa artificial.
|
EP2023939B1
(de)
|
2006-05-05 |
2012-06-27 |
Isis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulation der expression von pcsk9
|
DE102006020885A1
(de)
*
|
2006-05-05 |
2007-11-08 |
Qiagen Gmbh |
Einführung von Sequenzelementen in Nukleinsäuren
|
WO2007134181A2
(en)
*
|
2006-05-11 |
2007-11-22 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
US7666854B2
(en)
*
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
WO2007137156A2
(en)
|
2006-05-19 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of aha and therapeutic uses thereof
|
US7888498B2
(en)
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
EP2023938A4
(de)
*
|
2006-05-23 |
2010-11-10 |
Isis Pharmaceuticals Inc |
Modulation von chrebp-expression
|
US20090280188A1
(en)
*
|
2006-06-23 |
2009-11-12 |
Northwestern University |
Asymmetric functionalizated nanoparticles and methods of use
|
WO2008011473A2
(en)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hbxip
|
US20100137440A1
(en)
*
|
2006-09-11 |
2010-06-03 |
Yale University |
Lysine riboswitches, structure-based compound design with lysine riboswitches, and methods and compositions for use of and with lysine riboswitches
|
EP2064332B1
(de)
*
|
2006-09-14 |
2012-07-18 |
Ibis Biosciences, Inc. |
Gezielte gesamtgenomamplifizierung zur identifizierung von krankheitserregern
|
EP2081949B1
(de)
*
|
2006-09-22 |
2014-12-10 |
GE Healthcare Dharmacon, Inc. |
Dreiteilige oligonukleotidkomplexe und verfahren zum gene-silencing durch rna-interferenz
|
WO2008042156A1
(en)
*
|
2006-09-28 |
2008-04-10 |
Northwestern University |
Maximizing oligonucleotide loading on gold nanoparticle
|
WO2008063758A2
(en)
|
2006-10-05 |
2008-05-29 |
Massachussetts Institute Of Technology |
Multifunctional encoded particles for high-throughput analysis
|
WO2008136852A2
(en)
|
2006-11-01 |
2008-11-13 |
University Of Rochester |
Methods and compositions related to the structure and function of apobec3g
|
CA2672297A1
(en)
|
2006-12-11 |
2008-06-19 |
University Of Utah Research Foundation |
Compositions and methods for treating pathologic angiogenesis and vascular permeability
|
WO2008094370A2
(en)
|
2006-12-22 |
2008-08-07 |
University Of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
CN103966345A
(zh)
|
2007-02-09 |
2014-08-06 |
西北大学 |
检测细胞内标靶的颗粒
|
WO2008104002A2
(en)
*
|
2007-02-23 |
2008-08-28 |
Ibis Biosciences, Inc. |
Methods for rapid forensic dna analysis
|
CN101801185A
(zh)
|
2007-03-22 |
2010-08-11 |
耶鲁大学 |
与控制可变剪接的核糖开关有关的方法和组合物
|
US20100204266A1
(en)
*
|
2007-03-23 |
2010-08-12 |
Ibis Biosciences, INC |
Compositions for use in identification of mixed populations of bioagents
|
EP2905336A1
(de)
|
2007-03-29 |
2015-08-12 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression eines Gens von Ebola
|
EP2426219A1
(de)
|
2007-05-29 |
2012-03-07 |
Yale University |
Riboswitches sowie Verfahren und Zusammensetzungen zur Verwendung von und mit Riboswitches
|
EP2164994A4
(de)
*
|
2007-05-29 |
2010-07-21 |
Univ Yale Inc |
Verfahren und zusammensetzungen in verbindung mit riboswitches zu steuerung von alternativer spleissung und rna-verarbeitung
|
US8278425B2
(en)
|
2007-05-30 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
CA2689923A1
(en)
|
2007-05-30 |
2008-12-11 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
US9598724B2
(en)
|
2007-06-01 |
2017-03-21 |
Ibis Biosciences, Inc. |
Methods and compositions for multiple displacement amplification of nucleic acids
|
US7807372B2
(en)
*
|
2007-06-04 |
2010-10-05 |
Northwestern University |
Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
|
US8278426B2
(en)
|
2007-06-08 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
US8278283B2
(en)
*
|
2007-07-05 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
6-disubstituted or unsaturated bicyclic nucleic acid analogs
|
US8088904B2
(en)
|
2007-08-15 |
2012-01-03 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
AU2008296478B9
(en)
*
|
2007-08-28 |
2015-03-19 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
WO2009039466A1
(en)
|
2007-09-20 |
2009-03-26 |
Vanderbilt University |
Free solution measurement of molecular interactions by backscattering interferometry
|
WO2009039442A1
(en)
*
|
2007-09-21 |
2009-03-26 |
California Institute Of Technology |
Nfia in glial fate determination, glioma therapy and astrocytoma treatment
|
AU2008324068A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Baltic Technology Development, Ltd. |
Use of oligonucleotides with modified bases in hybridization of nucleic acids
|
US8916531B2
(en)
*
|
2007-11-20 |
2014-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
EP2617828B1
(de)
|
2007-12-10 |
2014-09-24 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
|
US7845686B2
(en)
*
|
2007-12-17 |
2010-12-07 |
S & B Technical Products, Inc. |
Restrained pipe joining system for plastic pipe
|
US20110117125A1
(en)
|
2008-01-02 |
2011-05-19 |
Tekmira Pharmaceuticals Corporation |
Compositions and methods for the delivery of nucleic acids
|
WO2009100320A2
(en)
*
|
2008-02-07 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
US10131904B2
(en)
|
2008-02-11 |
2018-11-20 |
Rxi Pharmaceuticals Corporation |
Modified RNAi polynucleotides and uses thereof
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
AU2009221775B2
(en)
|
2008-03-05 |
2015-05-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
EP2282744B1
(de)
|
2008-03-21 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit trizyklischen nukleosiden und anwendungsverfahren dafür
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
WO2009124238A1
(en)
*
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
ES2554168T3
(es)
|
2008-04-18 |
2015-12-16 |
Baxter International Inc. |
Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición
|
CA2722668A1
(en)
*
|
2008-04-29 |
2009-11-05 |
Wyeth Llc |
Methods for treating inflammation
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
EP2323667A4
(de)
*
|
2008-08-07 |
2012-07-25 |
Isis Pharmaceuticals Inc |
Modulierung der transthyretin-expression durch behandlung von zns-erkrankungen
|
AU2009275387B2
(en)
|
2008-08-25 |
2010-07-08 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
EP3208337A1
(de)
|
2008-09-02 |
2017-08-23 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
|
EP2349549B1
(de)
|
2008-09-16 |
2012-07-18 |
Ibis Biosciences, Inc. |
Mischpatronen, mischstationen und verwandte ausrüstungen, und system
|
EP2347254A2
(de)
|
2008-09-16 |
2011-07-27 |
Ibis Biosciences, Inc. |
Probenverarbeitungseinheiten, -systeme und damit verbundene verfahren
|
EP2344893B1
(de)
|
2008-09-16 |
2014-10-15 |
Ibis Biosciences, Inc. |
Mikroplatten-handhabungssysteme und verfahren
|
WO2010033248A2
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
DK2361256T3
(da)
|
2008-09-24 |
2013-07-01 |
Isis Pharmaceuticals Inc |
Cyclohexenyl-nukleinsyreanaloger
|
EP2356129B1
(de)
*
|
2008-09-24 |
2013-04-03 |
Isis Pharmaceuticals, Inc. |
Substituierte alpha-l-bicyclische nukleoside
|
EP3584320A1
(de)
|
2008-09-25 |
2019-12-25 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der serum-amyloid-a-genexpression
|
CN104119242B
(zh)
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
US8334372B2
(en)
|
2008-10-15 |
2012-12-18 |
Isis Pharmaceuticals, Inc. |
Modulation of factor 11 expression
|
CN106834291B
(zh)
|
2008-10-20 |
2020-09-29 |
阿尔尼拉姆医药品有限公司 |
抑制运甲状腺素蛋白表达的组合物和方法
|
EP2358397B1
(de)
|
2008-10-24 |
2020-01-01 |
Ionis Pharmaceuticals, Inc. |
5 - und 2 -bis-substituierte nukleoside und daraus hergestellte oligomere verbindungen
|
EP2447274B1
(de)
|
2008-10-24 |
2017-10-04 |
Ionis Pharmaceuticals, Inc. |
Oligomerverbindungen und Verfahren
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
KR101692880B1
(ko)
|
2008-11-24 |
2017-01-04 |
노오쓰웨스턴 유니버시티 |
다가 rna-나노입자 구조체
|
BRPI0923225A2
(pt)
|
2008-12-02 |
2016-10-04 |
Chiralgen Ltd |
metodo para sintese de acidos nucleicos modificados no atomo de fosforo
|
EP2370582B1
(de)
|
2008-12-04 |
2017-05-10 |
CuRNA, Inc. |
Behandlung von tumorsuppressorgen-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen das gen
|
ES2629630T3
(es)
|
2008-12-04 |
2017-08-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
|
EP2370580B1
(de)
|
2008-12-04 |
2019-09-11 |
CuRNA, Inc. |
Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirtuin 1
|
AU2009324534B2
(en)
|
2008-12-10 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
GNAQ targeted dsRNA compositions and methods for inhibiting expression
|
WO2010080616A1
(en)
|
2008-12-19 |
2010-07-15 |
Abbott Laboratories |
Molecular assay for diagnosis of malaria
|
US20110207143A1
(en)
*
|
2008-12-19 |
2011-08-25 |
Abbott Laboratories |
Diagnostic test for mutations in codons 12-13 of human k-ras
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
US20100184844A1
(en)
*
|
2009-01-08 |
2010-07-22 |
Northwestern University |
Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates
|
KR101546673B1
(ko)
*
|
2009-01-15 |
2015-08-25 |
삼성전자주식회사 |
전자 사진용 토너 및 그의 제조방법
|
US20100285473A1
(en)
|
2009-01-27 |
2010-11-11 |
John Wolff |
Thermophilic helicase dependent amplification technology with endpoint homogenous fluorescent detection
|
US20120101148A1
(en)
|
2009-01-29 |
2012-04-26 |
Alnylam Pharmaceuticals, Inc. |
lipid formulation
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
WO2010091308A2
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
US8536320B2
(en)
|
2009-02-06 |
2013-09-17 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
EP2396803A4
(de)
|
2009-02-12 |
2016-10-26 |
Ibis Biosciences Inc |
Ionisationssondenanordnungen
|
ES2560107T3
(es)
|
2009-02-12 |
2016-02-17 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
|
WO2010093906A2
(en)
|
2009-02-12 |
2010-08-19 |
Curna, Inc. |
Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
WO2010102058A2
(en)
|
2009-03-04 |
2010-09-10 |
Curna, Inc. |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
|
WO2010105209A1
(en)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
CA2755409C
(en)
|
2009-03-16 |
2019-04-30 |
Joseph Collard |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
JP5904935B2
(ja)
|
2009-03-17 |
2016-04-20 |
クルナ・インコーポレーテッド |
デルタ様1ホモログ(dlk1)に対する天然アンチセンス転写物の抑制によるdlk1関連疾患の治療
|
US9393564B2
(en)
|
2009-03-30 |
2016-07-19 |
Ibis Biosciences, Inc. |
Bioagent detection systems, devices, and methods
|
AU2010237001B2
(en)
|
2009-04-15 |
2016-07-07 |
Northwestern University |
Delivery of oligonucleotide-functionalized nanoparticles
|
EP3248618A1
(de)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
|
CA2760589C
(en)
|
2009-05-01 |
2019-08-20 |
Joseph Collard |
Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
|
CA3045126A1
(en)
|
2009-05-05 |
2010-11-11 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
KR20180094137A
(ko)
|
2009-05-05 |
2018-08-22 |
알닐람 파마슈티칼스 인코포레이티드 |
지질 조성물
|
CN102459596B
(zh)
|
2009-05-06 |
2016-09-07 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
KR101722541B1
(ko)
|
2009-05-06 |
2017-04-04 |
큐알엔에이, 인크. |
Ttp에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
|
WO2010132665A1
(en)
|
2009-05-15 |
2010-11-18 |
Yale University |
Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
|
ES2664590T3
(es)
|
2009-05-18 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con factores de reprogramación por inhibición del tránscrito antisentido natural a un factor de reprogramación
|
US8895527B2
(en)
|
2009-05-22 |
2014-11-25 |
Curna, Inc. |
Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
|
WO2010138806A2
(en)
|
2009-05-28 |
2010-12-02 |
Curna, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
US8158601B2
(en)
|
2009-06-10 |
2012-04-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulation
|
JP5944311B2
(ja)
|
2009-06-16 |
2016-07-05 |
クルナ・インコーポレーテッド |
コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
|
US8951981B2
(en)
|
2009-06-16 |
2015-02-10 |
Curna, Inc. |
Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
|
JP6073133B2
(ja)
|
2009-06-24 |
2017-02-01 |
クルナ・インコーポレーテッド |
腫瘍壊死因子受容体2(tnfr2)に対する天然アンチセンス転写物の抑制によるtnfr2関連疾患の治療
|
EP2446037B1
(de)
|
2009-06-26 |
2016-04-20 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem down-syndrom-gen durch hemmung des natürlichen antisense-transkripts zu einem down-syndrom-gen
|
MX342945B
(es)
|
2009-07-06 |
2016-10-18 |
Ontorii Inc * |
Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
|
US8950604B2
(en)
*
|
2009-07-17 |
2015-02-10 |
Ibis Biosciences, Inc. |
Lift and mount apparatus
|
WO2011008972A1
(en)
|
2009-07-17 |
2011-01-20 |
Ibis Biosciences, Inc. |
Systems for bioagent identification
|
WO2011014811A1
(en)
|
2009-07-31 |
2011-02-03 |
Ibis Biosciences, Inc. |
Capture primers and capture sequence linked solid supports for molecular diagnostic tests
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
EP2462153B1
(de)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexosenukleinsäureanaloga
|
WO2011020023A2
(en)
|
2009-08-14 |
2011-02-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
WO2011022420A1
(en)
|
2009-08-17 |
2011-02-24 |
Yale University |
Methylation biomarkers and methods of use
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
ES2599076T3
(es)
|
2009-09-02 |
2017-01-31 |
Genentech, Inc. |
Smoothened mutante y métodos de utilización del mismo
|
US20110091882A1
(en)
*
|
2009-10-02 |
2011-04-21 |
Ibis Biosciences, Inc. |
Determination of methylation status of polynucleotides
|
EP3225695A1
(de)
*
|
2009-10-15 |
2017-10-04 |
Ibis Biosciences, Inc. |
Multiple-displacement-amplifikation
|
SG10201406631TA
(en)
*
|
2009-10-16 |
2014-11-27 |
Melinta Therapeutics Inc |
Antimicrobial compounds and methods of making and using the same
|
JP2013508299A
(ja)
|
2009-10-16 |
2013-03-07 |
リブ−エックス ファーマシューティカルズ,インコーポレイテッド |
抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
|
CN102712657A
(zh)
|
2009-10-16 |
2012-10-03 |
Rib-X制药公司 |
抗微生物化合物和其制备和使用方法
|
KR20120105446A
(ko)
|
2009-10-22 |
2012-09-25 |
제넨테크, 인크. |
대식세포-자극 단백질의 헵신 활성화를 조정하기 위한 방법 및 조성물
|
JP6147502B2
(ja)
|
2009-10-27 |
2017-06-14 |
スウィフト バイオサイエンシーズ, インコーポレイテッド |
ポリヌクレオチドプライマー及びプローブ
|
KR20120136345A
(ko)
|
2009-10-30 |
2012-12-18 |
노오쓰웨스턴 유니버시티 |
주형화된 나노컨쥬게이트
|
WO2011056215A1
(en)
|
2009-11-03 |
2011-05-12 |
Landers James P |
Versatile, visible method for detecting polymeric analytes
|
JP2013511285A
(ja)
|
2009-11-23 |
2013-04-04 |
スイフト・バイオサイエンシズ・インコーポレイテツド |
一本鎖標的分子を伸長させるデバイス
|
AU2010324686B2
(en)
|
2009-11-30 |
2016-05-19 |
Genentech, Inc. |
Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
|
ES2661813T3
(es)
|
2009-12-16 |
2018-04-04 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la peptidasa del factor de transcripción de membrana, sitio 1 (mbtps1) mediante inhibición del transcrito antisentido natural al gen mbtps1
|
CA2782375C
(en)
|
2009-12-23 |
2023-10-31 |
Opko Curna, Llc |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
JP5934106B2
(ja)
|
2009-12-23 |
2016-06-15 |
カッパーアールエヌエー,インコーポレイテッド |
肝細胞増殖因子(hgf)に対する天然アンチセンス転写物の阻害によるhgf関連性疾患の治療
|
EP2519634B1
(de)
|
2009-12-29 |
2016-06-01 |
CuRNA, Inc. |
Behandlung von durch das tumorprotein 63 (p63) vermittelten erkrankungen durch das natürliche antisense-transkript für p63
|
US8921334B2
(en)
|
2009-12-29 |
2014-12-30 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
|
KR101878501B1
(ko)
|
2010-01-04 |
2018-08-07 |
큐알엔에이, 인크. |
인터페론 조절 인자 8 (irf8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (irf8) 관련된 질환의 치료
|
KR101853509B1
(ko)
|
2010-01-06 |
2018-04-30 |
큐알엔에이, 인크. |
췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
|
WO2011085102A1
(en)
|
2010-01-11 |
2011-07-14 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
ES2664866T3
(es)
|
2010-01-11 |
2018-04-23 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg
|
SG182365A1
(en)
|
2010-01-12 |
2012-08-30 |
Univ Yale |
Structured rna motifs and compounds and methods for their use
|
CN102782135A
(zh)
|
2010-01-25 |
2012-11-14 |
库尔纳公司 |
通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
|
US20130028889A1
(en)
|
2010-02-04 |
2013-01-31 |
Ico Therapeutics Inc. |
Dosing regimens for treating and preventing ocular disorders using c-raf antisense
|
US8962586B2
(en)
|
2010-02-22 |
2015-02-24 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
US8877897B2
(en)
|
2010-02-23 |
2014-11-04 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
ES2743600T3
(es)
|
2010-03-12 |
2020-02-20 |
Brigham & Womens Hospital Inc |
Métodos de tratamiento de los trastornos inflamatorios vasculares
|
US20130101512A1
(en)
|
2010-03-12 |
2013-04-25 |
Chad A. Mirkin |
Crosslinked polynucleotide structure
|
WO2011115817A1
(en)
|
2010-03-16 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
Methods of preparing 2'-o-substituted purine nucleosides
|
WO2011115818A1
(en)
|
2010-03-17 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2550000A4
(de)
|
2010-03-24 |
2014-03-26 |
Advirna Inc |
Selbstfreisetzende rnai-verbindungen von reduzierter grösse
|
WO2011119871A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Phrmaceuticals Corporation |
Rna interference in ocular indications
|
JP6060071B2
(ja)
|
2010-03-24 |
2017-01-11 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
皮膚および線維症適用におけるrna干渉
|
AU2011230496B2
(en)
|
2010-03-26 |
2015-09-17 |
Integrated Dna Technologies, Inc. |
Methods for enhancing nucleic acid hybridization
|
US9506057B2
(en)
|
2010-03-26 |
2016-11-29 |
Integrated Dna Technologies, Inc. |
Modifications for antisense compounds
|
US20120108799A1
(en)
|
2010-09-07 |
2012-05-03 |
Integrated Dna Technologies, Inc. |
Modifications for Antisense Compounds
|
US8889350B2
(en)
|
2010-03-26 |
2014-11-18 |
Swift Biosciences, Inc. |
Methods and compositions for isolating polynucleotides
|
JP5860029B2
(ja)
|
2010-03-29 |
2016-02-16 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
トランスチレチン(TTR)関連眼アミロイドーシスのためのsiRNA療法
|
CN102858979B
(zh)
|
2010-04-09 |
2018-01-26 |
库尔纳公司 |
通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
|
WO2011133695A2
(en)
|
2010-04-20 |
2011-10-27 |
Swift Biosciences, Inc. |
Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
WO2011133876A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
US9127033B2
(en)
|
2010-04-28 |
2015-09-08 |
Isis Pharmaceuticals, Inc. |
5′ modified nucleosides and oligomeric compounds prepared therefrom
|
CN103154014B
(zh)
|
2010-04-28 |
2015-03-25 |
Isis制药公司 |
修饰核苷、其类似物以及由它们制备的寡聚化合物
|
EP2606057B1
(de)
|
2010-04-28 |
2016-06-15 |
Ionis Pharmaceuticals, Inc. |
Modifizierte 5' diphosphat-nukleoside und daraus hergestellte oligomere verbindungen
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
SI2563920T1
(sl)
|
2010-04-29 |
2017-05-31 |
Ionis Pharmaceuticals, Inc. |
Modulacija izražanja transtiretina
|
WO2011139387A1
(en)
|
2010-05-03 |
2011-11-10 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
BR112012028010A2
(pt)
|
2010-05-03 |
2017-09-26 |
Genentech Inc |
anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
US8628914B2
(en)
|
2010-05-26 |
2014-01-14 |
Qiagen Gaithersburg, Inc. |
Quantitative helicase assay
|
WO2011150226A1
(en)
|
2010-05-26 |
2011-12-01 |
Landers James P |
Method for detecting nucleic acids based on aggregate formation
|
NO2576783T3
(de)
|
2010-05-26 |
2018-04-28 |
|
|
CA2801066C
(en)
|
2010-06-02 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
WO2011156434A2
(en)
|
2010-06-07 |
2011-12-15 |
Firefly Bioworks, Inc. |
Nucleic acid detection and quantification by post-hybridization labeling and universal encoding
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2580228B1
(de)
|
2010-06-08 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Substituierte 2 '-amino- und 2 '-thio-bicyclische nukleoside und daraus hergestellte oligomere verbindungen
|
US9638632B2
(en)
|
2010-06-11 |
2017-05-02 |
Vanderbilt University |
Multiplexed interferometric detection system and method
|
WO2011159836A2
(en)
|
2010-06-15 |
2011-12-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating interaction between proteins and target nucleic acids
|
WO2011163466A1
(en)
|
2010-06-23 |
2011-12-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (nrg-1)
|
US8980860B2
(en)
|
2010-07-14 |
2015-03-17 |
Curna, Inc. |
Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
|
US20130237585A1
(en)
|
2010-07-19 |
2013-09-12 |
University Of Rochester |
Modulation of dystrophia myotonica-protein kinase (dmpk) expression
|
WO2012021554A1
(en)
|
2010-08-09 |
2012-02-16 |
Yale University |
Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
|
JP5868324B2
(ja)
|
2010-09-24 |
2016-02-24 |
株式会社Wave Life Sciences Japan |
不斉補助基
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
EP2625292B1
(de)
|
2010-10-07 |
2018-12-05 |
The General Hospital Corporation |
Krebsbiomarker
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
CA2815212A1
(en)
|
2010-10-22 |
2012-04-26 |
Curna, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
DK2633052T3
(en)
|
2010-10-27 |
2018-07-16 |
Curna Inc |
TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1
|
US8569331B2
(en)
|
2010-11-01 |
2013-10-29 |
Arqule, Inc. |
Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds
|
WO2012064824A1
(en)
|
2010-11-09 |
2012-05-18 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
WO2012065143A1
(en)
|
2010-11-12 |
2012-05-18 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
CA3077910A1
(en)
|
2010-11-17 |
2012-05-24 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
WO2012097261A2
(en)
|
2011-01-14 |
2012-07-19 |
The General Hospital Corporation |
Methods targeting mir-128 for regulating cholesterol/lipid metabolism
|
WO2012106509A1
(en)
|
2011-02-02 |
2012-08-09 |
The Trustees Of Princeton University |
Sirtuin modulators as virus production modulators
|
WO2012106508A1
(en)
|
2011-02-02 |
2012-08-09 |
Pfizer Inc. |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
|
ES2818586T3
(es)
|
2011-02-07 |
2021-04-13 |
Governing Council Univ Toronto |
Biosondas y métodos de uso de las mismas
|
EP3467109A1
(de)
|
2011-02-08 |
2019-04-10 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
|
US9562853B2
(en)
|
2011-02-22 |
2017-02-07 |
Vanderbilt University |
Nonaqueous backscattering interferometric methods
|
SG193923A1
(en)
|
2011-03-29 |
2013-11-29 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of tmprss6 gene
|
EP3460064B8
(de)
|
2011-04-03 |
2024-03-20 |
The General Hospital Corporation d/b/a Massachusetts General Hospital |
Effiziente in-vivo-proteinexpression mittels modifizierter rna (mod-rna)
|
WO2012149154A1
(en)
|
2011-04-26 |
2012-11-01 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
WO2012151289A2
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system to detect aggregate formation on a substrate
|
WO2012151324A1
(en)
|
2011-05-02 |
2012-11-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
WO2012151268A1
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system for high throughput optical and label free detection of analytes
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
JP6188686B2
(ja)
|
2011-06-09 |
2017-08-30 |
カッパーアールエヌエー,インコーポレイテッド |
フラタキシン(fxn)への天然アンチセンス転写物の阻害によるfxn関連疾患の治療
|
SG10201800715PA
(en)
|
2011-06-21 |
2018-02-27 |
Alnylam Pharmaceuticals Inc |
Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
|
EP2723351B1
(de)
|
2011-06-21 |
2018-02-14 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
|
MX344807B
(es)
|
2011-06-21 |
2017-01-09 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3).
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
US9222093B2
(en)
|
2011-06-30 |
2015-12-29 |
The University Of Hong Kong |
Two-way, portable riboswitch mediated gene expression control device
|
WO2013012758A1
(en)
|
2011-07-19 |
2013-01-24 |
Ontorii, Inc. |
Methods for the synthesis of functionalized nucleic acids
|
EP2739735A2
(de)
|
2011-08-01 |
2014-06-11 |
Alnylam Pharmaceuticals, Inc. |
Verfahren zur verbesserung der erfolgsquote von hämatopoetischen stammzellentransplantaten
|
EP2742135B2
(de)
|
2011-08-11 |
2020-06-10 |
Ionis Pharmaceuticals, Inc. |
Rückgratmodifizierte gapmer verbindungen und ihre verwendungen
|
EP2751269B1
(de)
|
2011-08-29 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Verfahren und verbindungen für erkrankungen im zusammenhang mit repeat-expansion
|
WO2013033230A1
(en)
|
2011-08-29 |
2013-03-07 |
Isis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
AU2012308302A1
(en)
|
2011-09-14 |
2014-03-20 |
Northwestern University |
Nanoconjugates able to cross the blood-brain barrier
|
JP6129844B2
(ja)
|
2011-09-14 |
2017-05-17 |
ラナ セラピューティクス インコーポレイテッド |
多量体オリゴヌクレオチド化合物
|
WO2013040548A2
(en)
|
2011-09-17 |
2013-03-21 |
Yale University |
Fluoride-responsive riboswitchs, fluoride transporters, and methods of use
|
EP2766482B1
(de)
|
2011-10-11 |
2016-12-07 |
The Brigham and Women's Hospital, Inc. |
Mikro-rnas in neurodegenerativen erkrankungen
|
PT2766393T
(pt)
|
2011-10-14 |
2018-10-15 |
Hoffmann La Roche |
Anticorpos anti-htra1 e métodos de utilização
|
US9243291B1
(en)
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
DK2790736T3
(en)
|
2011-12-12 |
2018-05-07 |
Oncoimmunin Inc |
In vivo delivery of oligonucleotides
|
US9970061B2
(en)
|
2011-12-27 |
2018-05-15 |
Ibis Biosciences, Inc. |
Bioagent detection oligonucleotides
|
US20150025231A1
(en)
|
2012-01-11 |
2015-01-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for modulation of ikbkap splicing
|
EP3434789A1
(de)
|
2012-01-13 |
2019-01-30 |
Data2Bio |
Genotypisierung durch eine sequenzierung der nächsten generation
|
CN104395480B
(zh)
|
2012-03-13 |
2018-01-30 |
斯威夫特生物科学公司 |
用于通过核酸聚合酶对衬底多核苷酸进行大小受控的同聚物加尾的方法和组合物
|
CN110438125A
(zh)
|
2012-03-15 |
2019-11-12 |
科纳公司 |
通过抑制脑源神经营养因子(bdnf)的天然反义转录物治疗bdnf相关疾病
|
CA2907072A1
(en)
|
2012-03-16 |
2013-09-19 |
Valerion Therapeutics, Llc |
Antisense conjugates for decreasing expression of dmpk
|
EP2831231A1
(de)
|
2012-03-30 |
2015-02-04 |
Isis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur modulation der tau-expression zur verringerung von anfällen und modifizierung eines neurodegenerativen syndroms
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2850092B1
(de)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclische nukleinsäureanaloga
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
AU2013248981B2
(en)
|
2012-04-20 |
2018-11-29 |
Aptamir Therapeutics, Inc. |
Mirna modulators of thermogenesis
|
EP2839006B1
(de)
|
2012-04-20 |
2018-01-03 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
US9273949B2
(en)
|
2012-05-11 |
2016-03-01 |
Vanderbilt University |
Backscattering interferometric methods
|
KR102028784B1
(ko)
|
2012-05-16 |
2019-10-04 |
트랜슬레이트 바이오 인코포레이티드 |
유전자 발현을 조절하기 위한 조성물 및 방법
|
DK2850186T3
(en)
|
2012-05-16 |
2019-04-08 |
Translate Bio Ma Inc |
COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
WO2013173789A2
(en)
|
2012-05-17 |
2013-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
WO2013181665A1
(en)
|
2012-06-01 |
2013-12-05 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
US9487780B2
(en)
|
2012-06-01 |
2016-11-08 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
WO2013184209A1
(en)
|
2012-06-04 |
2013-12-12 |
Ludwig Institute For Cancer Research Ltd. |
Mif for use in methods of treating subjects with a neurodegenerative disorder
|
US20130330389A1
(en)
|
2012-06-08 |
2013-12-12 |
The Regents Of The University Of Michigan |
Ultrasound-triggerable agents for tissue engineering
|
CN104684893B
(zh)
|
2012-07-13 |
2016-10-26 |
日本波涛生命科学公司 |
不对称辅助基团
|
RU2677639C2
(ru)
|
2012-07-13 |
2019-01-18 |
Шин Ниппон Биомедикал Лэбораториз, Лтд. |
Хиральный адъювант нуклеиновой кислоты
|
KR102450907B1
(ko)
|
2012-07-13 |
2022-10-04 |
웨이브 라이프 사이언시스 리미티드 |
키랄 제어
|
US20140038182A1
(en)
|
2012-07-17 |
2014-02-06 |
Dna Logix, Inc. |
Cooperative primers, probes, and applications thereof
|
CA2880833A1
(en)
|
2012-08-03 |
2014-02-06 |
Aptamir Therapeutics, Inc. |
Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
|
EP2885312A4
(de)
|
2012-08-15 |
2016-01-20 |
Isis Pharmaceuticals Inc |
Verfahren zur herstellung oligomerer verbindungen unter verwendung von modifizierten kappungsprotokollen
|
EP3421602B1
(de)
|
2012-09-06 |
2021-03-03 |
The University of Chicago |
Antisense-polynukleotide zur induktion von exon-skipping sowie verfahren zur behandlung von muskeldystrophien
|
WO2014059353A2
(en)
|
2012-10-11 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
WO2014059356A2
(en)
|
2012-10-12 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
EP4144845B1
(de)
|
2012-10-12 |
2024-04-24 |
Ionis Pharmaceuticals, Inc. |
Antisense-verbindungen und verwendungen davon
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
CA3201145A1
(en)
|
2012-10-26 |
2014-05-01 |
Geron Corporation |
C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
|
CA2890207A1
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
WO2014093537A1
(en)
|
2012-12-11 |
2014-06-19 |
Isis Pharmaceuticals, Inc. |
Competitive modulation of micrornas
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
US10260069B2
(en)
|
2013-02-04 |
2019-04-16 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
WO2014160129A2
(en)
|
2013-03-14 |
2014-10-02 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
WO2014153206A2
(en)
|
2013-03-14 |
2014-09-25 |
Andes Biotechnologies S.A. |
Methods for detecting and treating multiple myeloma
|
CN105229150A
(zh)
|
2013-03-14 |
2016-01-06 |
安第斯生物技术股份有限公司 |
用于治疗癌症干细胞的反义寡核苷酸
|
BR112015022156A2
(pt)
|
2013-03-14 |
2017-11-14 |
Isis Pharmaceuticals Inc |
composições e métodos para modular a expressão de tau
|
US9347095B2
(en)
|
2013-03-15 |
2016-05-24 |
Bio-Rad Laboratories, Inc. |
Digital assays for mutation detection
|
WO2014160871A2
(en)
|
2013-03-27 |
2014-10-02 |
The General Hospital Corporation |
Methods and agents for treating alzheimer's disease
|
JP2016522679A
(ja)
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
CRISPR/Cas系を用いたゲノム編集の治療的使用
|
US9677075B2
(en)
|
2013-04-23 |
2017-06-13 |
Northwestern University |
Metal-ligand coordination polymer nanoparticles and methods for making
|
US9127276B2
(en)
|
2013-05-01 |
2015-09-08 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
CN105452463B
(zh)
|
2013-05-22 |
2019-06-21 |
阿尔尼拉姆医药品有限公司 |
Tmprss6 irna组合物及其使用方法
|
BR112015029139B1
(pt)
|
2013-05-22 |
2022-07-12 |
Alnylam Pharmaceuticals, Inc |
Agente de rnai de fita dupla para inibição da expressão de serpina1 em uma célula, seus usos, bem como composição farmacêutica e método in vitro de inibição da expressão de serpina1 em uma célula
|
US20160113911A1
(en)
|
2013-06-06 |
2016-04-28 |
The General Hospital Corporation |
Methods and compositions for the treatment of cancer
|
JP6869720B2
(ja)
|
2013-06-13 |
2021-05-12 |
アンチセンス セラピューティクス リミテッド |
併用療法
|
EP3011028B1
(de)
|
2013-06-21 |
2019-06-12 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur modulation von zielnukleinsäuren
|
US10077236B2
(en)
|
2013-07-15 |
2018-09-18 |
The Regents Of The University Of California |
Azacyclic constrained analogs of FTY720
|
TWI657819B
(zh)
|
2013-07-19 |
2019-05-01 |
美商Ionis製藥公司 |
用於調節τ蛋白表現之組合物
|
WO2015017675A2
(en)
|
2013-07-31 |
2015-02-05 |
Isis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
GB201313897D0
(en)
|
2013-08-02 |
2013-09-18 |
Maersk Olie & Gas |
Conformance control in enhanced oil recovery
|
EP4079745A1
(de)
|
2013-08-08 |
2022-10-26 |
The Scripps Research Institute |
Verfahren zur ortsspezifischen enzymatischen in-vitro-markierung von nukleinsäuren durch zugabe von unnatürlichen nukleotiden
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
AU2014315045A1
(en)
|
2013-09-09 |
2016-03-24 |
Melinta Therapeutics, Inc. |
Antimicrobial compounds and methods of making and using the same
|
KR20160070066A
(ko)
|
2013-09-09 |
2016-06-17 |
멜린타 테라퓨틱스, 인크. |
항균 화합물, 및 이의 제조 방법 및 이용 방법
|
US9943604B2
(en)
|
2013-09-20 |
2018-04-17 |
Ionis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
MX2016004230A
(es)
|
2013-10-02 |
2016-10-21 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen lect2.
|
SG11201602631XA
(en)
|
2013-10-04 |
2016-05-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of the alas1 gene
|
EP3055426B1
(de)
|
2013-10-09 |
2019-06-19 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Nachweis von hepatitis delta virus (hdv) zur diagnose und behandlung von sjögren-syndrom und lymphom
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
EP3502270B1
(de)
|
2013-10-21 |
2020-03-18 |
The General Hospital Corporation |
Verfahren im zusammenhang mit zirkulierenden tumorzellclustern und mit der behandlung von krebs
|
WO2015066708A1
(en)
|
2013-11-04 |
2015-05-07 |
Northwestern University |
Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
|
WO2015070173A1
(en)
|
2013-11-08 |
2015-05-14 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for detecting oligonucleotides
|
EP3750997A1
(de)
|
2013-12-02 |
2020-12-16 |
Ionis Pharmaceuticals, Inc. |
Antisense-verbindungen und verwendungen davon
|
CN113151180A
(zh)
|
2013-12-02 |
2021-07-23 |
菲奥医药公司 |
癌症的免疫治疗
|
CA2932122C
(en)
|
2013-12-03 |
2022-04-19 |
Northwestern University |
Liposomal particles, methods of making same and uses thereof
|
WO2015085183A2
(en)
|
2013-12-06 |
2015-06-11 |
Swift Biosciences, Inc. |
Cleavable competitor polynucleotides
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
AU2014362262B2
(en)
|
2013-12-12 |
2021-05-13 |
Alnylam Pharmaceuticals, Inc. |
Complement component iRNA compositions and methods of use thereof
|
CN106456694B
(zh)
|
2013-12-20 |
2020-06-30 |
通用医疗公司 |
与循环肿瘤细胞相关的方法和测定法
|
US10322173B2
(en)
|
2014-01-15 |
2019-06-18 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
US10149905B2
(en)
|
2014-01-15 |
2018-12-11 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
|
JPWO2015108047A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
KR20230152178A
(ko)
|
2014-01-16 |
2023-11-02 |
웨이브 라이프 사이언시스 리미티드 |
키랄 디자인
|
DK3102197T3
(en)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened mutant and methods for its use
|
CN113057959A
(zh)
|
2014-02-11 |
2021-07-02 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
WO2015142910A1
(en)
|
2014-03-17 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
CN106103717A
(zh)
|
2014-03-19 |
2016-11-09 |
Ionis制药公司 |
用于调节共济失调蛋白2表达的组合物
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
SG11201608109TA
(en)
|
2014-04-01 |
2016-10-28 |
Ionis Pharmaceuticals Inc |
Compositions for modulating sod-1 expression
|
EP3129493B1
(de)
|
2014-04-09 |
2021-07-07 |
The Scripps Research Institute |
Import von unnatürlichen oder modifizierten nukleosid-triphosphaten in zellen mittels nukleinsäure-triphosphattransportern
|
WO2015164693A1
(en)
|
2014-04-24 |
2015-10-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
CA2947270A1
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic acids targeting mdm2 or mycn
|
WO2015168172A1
(en)
|
2014-04-28 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
SI3137605T1
(sl)
|
2014-05-01 |
2021-02-26 |
Ionis Pharmaceuticals, Inc. |
Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega
|
KR102369736B1
(ko)
|
2014-05-01 |
2022-03-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
보체 인자 b 발현을 조절하기 위한 조성물 및 방법
|
KR102149571B1
(ko)
|
2014-05-01 |
2020-08-31 |
아이오니스 파마수티컬즈, 인코포레이티드 |
성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
SG10202104570TA
(en)
|
2014-05-22 |
2021-06-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
CN106659758A
(zh)
|
2014-06-02 |
2017-05-10 |
儿童医疗中心有限公司 |
用于免疫调节的组合物和方法
|
CN106535876B
(zh)
|
2014-06-04 |
2020-09-11 |
埃克西奎雷股份有限公司 |
免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用
|
AU2015272128B2
(en)
|
2014-06-10 |
2021-10-28 |
Erasmus University Medical Center Rotterdam |
Antisense oligonucleotides useful in treatment of Pompe disease
|
CN106414738A
(zh)
|
2014-06-24 |
2017-02-15 |
雅培分子公司 |
人kras中单核苷酸多态性的检测
|
WO2015200697A1
(en)
|
2014-06-25 |
2015-12-30 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
US9951327B1
(en)
|
2014-07-17 |
2018-04-24 |
Integrated Dna Technologies, Inc. |
Efficient and rapid method for assembling and cloning double-stranded DNA fragments
|
US10653747B2
(en)
|
2014-07-31 |
2020-05-19 |
Uab Research Foundation |
ApoE mimetic peptides and higher potency to clear plasma cholesterol
|
EP3183007B1
(de)
|
2014-08-19 |
2020-06-17 |
Northwestern University |
Therapeutika mit protein/oligonukleotid-kernschalennanopartikeln
|
CA2958577A1
(en)
|
2014-08-20 |
2016-02-25 |
Northwestern University |
Biocompatible infinite coordination polymer nanoparticle-nucleic acid conjugates for antisense gene regulation
|
KR102631505B1
(ko)
|
2014-08-29 |
2024-02-01 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
EP3185910A4
(de)
|
2014-08-29 |
2018-01-10 |
Children's Medical Center Corporation |
Verfahren und zusammensetzungen zur krebsbehandlung
|
KR20230037676A
(ko)
|
2014-09-05 |
2023-03-16 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
EP3663403A1
(de)
|
2014-09-26 |
2020-06-10 |
University of Massachusetts |
Rna-modulierende stoffe
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
WO2016069694A2
(en)
|
2014-10-30 |
2016-05-06 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
US10287584B2
(en)
|
2014-11-12 |
2019-05-14 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of COMP
|
CA2968114A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
AU2015349680A1
(en)
|
2014-11-21 |
2017-06-08 |
Northwestern University |
The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
|
US9517270B2
(en)
|
2014-12-08 |
2016-12-13 |
The Board Of Regents Of The University Of Texas System |
Lipocationic polymers and uses thereof
|
CN107532162A
(zh)
|
2014-12-12 |
2018-01-02 |
托德·M·伍尔夫 |
用于利用寡核苷酸编辑细胞中核酸的组合物和方法
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
EP3247988A4
(de)
|
2015-01-23 |
2018-12-19 |
Vanderbilt University |
Robustes interferometer und verfahren zur verwendung davon
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
AU2016219263B2
(en)
|
2015-02-13 |
2022-12-01 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
|
US20180200387A1
(en)
|
2015-02-23 |
2018-07-19 |
Crispr Therapeutics Ag |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
SG11201707346RA
(en)
|
2015-03-11 |
2017-10-30 |
Melinta Therapeutics Inc |
Antimicrobial compounds and methods of making and using the same
|
KR20180020125A
(ko)
|
2015-03-27 |
2018-02-27 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
변형된 t 세포 및 이의 제조 및 사용 방법
|
US10961532B2
(en)
|
2015-04-07 |
2021-03-30 |
The General Hospital Corporation |
Methods for reactivating genes on the inactive X chromosome
|
HUE052604T2
(hu)
|
2015-04-08 |
2021-05-28 |
Univ Chicago |
Készítmények és eljárások 2C típusú végtag-öv izomdisztrófia javítására exon-átugrás alkalmazásával
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
EP3310918B1
(de)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Gegen hydroxysäureoxidase (glycolat-oxidase, hao1) gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
EP3314250A4
(de)
|
2015-06-26 |
2018-12-05 |
Beth Israel Deaconess Medical Center, Inc. |
Auf tetraspanin 33 (tspann33) in myeloidabgeleiteten suppressorzellen abzielende krebstherapie
|
US10590425B2
(en)
|
2015-06-29 |
2020-03-17 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
US11414657B2
(en)
|
2015-06-29 |
2022-08-16 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
KR20180026739A
(ko)
|
2015-07-06 |
2018-03-13 |
알엑스아이 파마슈티칼스 코포레이션 |
슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
WO2017011276A1
(en)
|
2015-07-10 |
2017-01-19 |
Ionis Pharmaceuticals, Inc. |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
US10941176B2
(en)
|
2015-07-28 |
2021-03-09 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
US20180237774A1
(en)
|
2015-08-04 |
2018-08-23 |
Yeda Research And Development Co. Ltd. |
Methods of screening for riboswitches and attenuators
|
CN114525280A
(zh)
|
2015-09-02 |
2022-05-24 |
阿尔尼拉姆医药品有限公司 |
程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
|
JP7041616B2
(ja)
|
2015-09-14 |
2022-03-24 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
リポカチオン性デンドリマーおよびその使用
|
RU2018113709A
(ru)
|
2015-09-24 |
2019-10-30 |
Айонис Фармасьютикалз, Инк. |
Модуляторы экспрессии kras
|
JP2018532402A
(ja)
|
2015-09-24 |
2018-11-08 |
クリスパー セラピューティクス アーゲー |
Rnaプログラム可能エンドヌクレアーゼの新規のファミリーならびにゲノム編集および他の適用におけるそれらの使用
|
CN108366990B
(zh)
|
2015-09-24 |
2021-09-03 |
加利福尼亚大学董事会 |
合成的鞘脂类分子、药物、它们的合成方法及治疗方法
|
EP4285912A2
(de)
|
2015-09-25 |
2023-12-06 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur modulation von ataxin 3-expression
|
WO2017058672A1
(en)
|
2015-09-29 |
2017-04-06 |
The Regents Of The University Of Michigan Office Of Technology Transfer |
Biodegradable hydrogel for tissue expansion
|
US11021707B2
(en)
|
2015-10-19 |
2021-06-01 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
|
CA3000931A1
(en)
|
2015-10-28 |
2017-05-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of duchenne muscular dystrophy
|
MX2018004509A
(es)
|
2015-10-30 |
2018-08-01 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso de los mismos.
|
EP3370734B1
(de)
|
2015-11-05 |
2023-01-04 |
Children's Hospital Los Angeles |
Antisense-oligo zur verwendung bei der behandlung von akuter myeloischer leukämie
|
EP3371305A1
(de)
|
2015-11-06 |
2018-09-12 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung der glycogenspeicherkrankheit des typs 1a
|
JP2018531605A
(ja)
|
2015-11-06 |
2018-11-01 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
アポリポタンパク質(a)発現の調節
|
EP4119569A1
(de)
|
2015-11-06 |
2023-01-18 |
Ionis Pharmaceuticals, Inc. |
Konjugierte antisense-verbindungen zur verwendung in der therapie
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
JP6932698B2
(ja)
|
2015-12-01 |
2021-09-08 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG |
アルファ1アンチトリプシン欠乏症の治療のための材料および方法
|
US11058709B1
(en)
|
2015-12-04 |
2021-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
CA3007152A1
(en)
|
2015-12-07 |
2017-06-15 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for pompe disease
|
US11761007B2
(en)
|
2015-12-18 |
2023-09-19 |
The Scripps Research Institute |
Production of unnatural nucleotides using a CRISPR/Cas9 system
|
BR112018012894A2
(pt)
|
2015-12-23 |
2018-12-04 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de esclerose lateral amiotrófica e/ou degeneração lobular frontotemporal
|
CA3006599A1
(en)
|
2016-01-05 |
2017-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing lrrk2 expression
|
WO2017132483A1
(en)
|
2016-01-29 |
2017-08-03 |
Vanderbilt University |
Free-solution response function interferometry
|
EP3411078A1
(de)
|
2016-02-02 |
2018-12-12 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn-syndrom
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
EP3416689B1
(de)
|
2016-02-18 |
2023-01-18 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn syndrome
|
WO2017147087A1
(en)
|
2016-02-25 |
2017-08-31 |
The Brigham And Women's Hospital, Inc. |
Treatment methods for fibrosis targeting smoc2
|
US11364258B2
(en)
|
2016-03-04 |
2022-06-21 |
Rhode Island Hospital |
Methods for treating chondrosarcoma using microrna(miR)
|
CA3013797A1
(en)
|
2016-03-09 |
2017-09-14 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for inhibiting pmp22 expression
|
US10961271B2
(en)
|
2016-03-16 |
2021-03-30 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
EP3429632B1
(de)
|
2016-03-16 |
2023-01-04 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von erblicher haemochromatose
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
US10731166B2
(en)
|
2016-03-18 |
2020-08-04 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
US20190142856A1
(en)
|
2016-04-13 |
2019-05-16 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing c9orf72 expression
|
MX2018012729A
(es)
|
2016-04-18 |
2019-07-04 |
Crispr Therapeutics Ag |
Materiales y metodos para el tratamiento de hemoglobinopatias.
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
WO2017201076A1
(en)
|
2016-05-16 |
2017-11-23 |
The Board Of Regents Of The University Of Texas System |
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
|
WO2017205686A1
(en)
|
2016-05-25 |
2017-11-30 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
EP3469083A1
(de)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
|
US11708614B2
(en)
|
2016-06-15 |
2023-07-25 |
Streck Llc |
Assays and methods for determining microbial resistance
|
EP3471781A4
(de)
|
2016-06-17 |
2020-05-06 |
Ionis Pharmaceuticals, Inc. |
Modulierung der gys1-expression
|
ES2929047T3
(es)
|
2016-06-24 |
2022-11-24 |
Scripps Research Inst |
Transportador de nucleósido trifosfato novedoso y usos del mismo
|
EP3478313B1
(de)
|
2016-06-29 |
2022-05-04 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von amyotropher lateralsklerose (als) und anderen verwandten erkrankungen
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
US11564997B2
(en)
|
2016-06-29 |
2023-01-31 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
US11801313B2
(en)
|
2016-07-06 |
2023-10-31 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
AU2017292173B2
(en)
|
2016-07-06 |
2022-01-13 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
US11253601B2
(en)
|
2016-07-11 |
2022-02-22 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
IL264216B2
(en)
|
2016-07-15 |
2024-04-01 |
Ionis Pharmaceuticals Inc |
Compounds and Methods for Modulating SMN2
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
WO2018039629A2
(en)
|
2016-08-25 |
2018-03-01 |
Northwestern University |
Micellar spherical nucleic acids from thermoresponsive, traceless templates
|
SG10201607303YA
(en)
|
2016-09-01 |
2018-04-27 |
Agency Science Tech & Res |
Antisense oligonucleotides to induce exon skipping
|
WO2018055577A1
(en)
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
EP3522898A4
(de)
|
2016-10-06 |
2020-05-27 |
Ionis Pharmaceuticals, Inc. |
Verfahren zum konjugieren von oligomeren verbindungen
|
SG10201609048RA
(en)
|
2016-10-28 |
2018-05-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
US11459568B2
(en)
|
2016-10-31 |
2022-10-04 |
University Of Massachusetts |
Targeting microRNA-101-3p in cancer therapy
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
US11447519B2
(en)
|
2016-11-10 |
2022-09-20 |
San Diego State University Research Foundation |
Compounds for fluorescence sensing of duplex formation
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
EP3548620A4
(de)
|
2016-12-02 |
2020-07-22 |
Cold Spring Harbor Laboratory |
Modulation der lnc05-expression
|
JP7206214B2
(ja)
|
2016-12-13 |
2023-01-17 |
シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) |
インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
|
KR20230166146A
(ko)
|
2016-12-16 |
2023-12-06 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
|
EP3571321A1
(de)
|
2017-01-23 |
2019-11-27 |
Regeneron Pharmaceuticals, Inc. |
Varianten von hydroxysteroid-17-beta-dehydrogenase 13 (hsd17b13) und verwendungen davon
|
US11559588B2
(en)
|
2017-02-22 |
2023-01-24 |
Crispr Therapeutics Ag |
Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
|
WO2018154462A2
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
WO2018154418A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
AU2018224387A1
(en)
|
2017-02-22 |
2019-09-05 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
US11407997B2
(en)
|
2017-02-22 |
2022-08-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
|
WO2018165564A1
(en)
|
2017-03-09 |
2018-09-13 |
Ionis Pharmaceuticals, Inc. |
Morpholino modified oligomeric compounds
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
WO2018183969A1
(en)
|
2017-03-30 |
2018-10-04 |
California Institute Of Technology |
Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform
|
MX2019012295A
(es)
|
2017-04-14 |
2020-02-07 |
Tollnine Inc |
Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
|
CN110913898B
(zh)
|
2017-04-18 |
2024-04-05 |
阿尔尼拉姆医药品有限公司 |
具有乙肝病毒(hbv)感染的受试者的治疗方法
|
WO2018193428A1
(en)
|
2017-04-20 |
2018-10-25 |
Synthena Ag |
Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
|
EP3612546B1
(de)
|
2017-04-20 |
2022-07-13 |
Synthena AG |
Modifizierte oligomere verbindungen mit tricyclischen dna-nukleosiden und verwendungen davon
|
US20200384115A1
(en)
|
2017-04-21 |
2020-12-10 |
The Broad Institute , Inc. |
Targeted delivery to beta cells
|
US11433131B2
(en)
|
2017-05-11 |
2022-09-06 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (SNAs)
|
CA3062506A1
(en)
|
2017-05-12 |
2019-05-23 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
US11597744B2
(en)
|
2017-06-30 |
2023-03-07 |
Sirius Therapeutics, Inc. |
Chiral phosphoramidite auxiliaries and methods of their use
|
US20200131555A1
(en)
|
2017-07-11 |
2020-04-30 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
MX2020000387A
(es)
|
2017-07-13 |
2020-08-17 |
Univ Northwestern |
Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.
|
EP3652317A1
(de)
|
2017-07-13 |
2020-05-20 |
Alnylam Pharmaceuticals, Inc. |
Lactatdehydrogenase-a (ldha)-irna-zusammensetzungen und verfahren zu ihrer verwendung
|
SG11202000939PA
(en)
|
2017-08-03 |
2020-02-27 |
Synthorx Inc |
Cytokine conjugates for the treatment of proliferative and infectious diseases
|
WO2019036613A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
WO2019060442A1
(en)
|
2017-09-19 |
2019-03-28 |
Alnylam Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR TREATMENT OF TRANSTHYRETIN MEDIATED AMYLOSIS (TTR)
|
MA50833A
(fr)
|
2017-10-17 |
2020-08-26 |
Bayer Healthcare Llc |
Compositions et méthodes pour l'édition génique pour l'hémophilie a
|
EP3701029A1
(de)
|
2017-10-26 |
2020-09-02 |
Vertex Pharmaceuticals Incorporated |
Materialien und verfahren zur behandlung von hämoglobinopathien
|
AU2018360697A1
(en)
|
2017-11-01 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
EP3707256A1
(de)
|
2017-11-09 |
2020-09-16 |
CRISPR Therapeutics AG |
Selbstinaktivierende (sin) crispr/cas- oder crispr/cpf1-systeme und verwendungen davon
|
WO2019099610A1
(en)
|
2017-11-16 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
AU2018372763A1
(en)
|
2017-11-21 |
2020-05-28 |
Bayer Healthcare Llc |
Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa
|
CA3084955A1
(en)
|
2017-12-05 |
2019-06-13 |
Vertex Pharmaceuticals Incorporated |
Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
|
US11725208B2
(en)
|
2017-12-14 |
2023-08-15 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
WO2019118935A1
(en)
|
2017-12-14 |
2019-06-20 |
Casebia Therapeutics Limited Liability Partnership |
Novel rna-programmable endonuclease systems and their use in genome editing and other applications
|
MX2020006012A
(es)
|
2017-12-18 |
2020-09-14 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni de la caja 1 del grupo de alta movilidad (hmgb1) y métodos de uso de las mismas.
|
WO2019123430A1
(en)
|
2017-12-21 |
2019-06-27 |
Casebia Therapeutics Llp |
Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
CN111836892A
(zh)
|
2017-12-21 |
2020-10-27 |
克里斯珀医疗股份公司 |
用于治疗2a型乌谢尔综合征的材料和方法
|
EP3737387A1
(de)
|
2018-01-12 |
2020-11-18 |
Bristol-Myers Squibb Company |
Antisense oligonukleotide zum targeting von alpha-synuklein und deren verwendung
|
CA3088180A1
(en)
|
2018-01-12 |
2019-07-18 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting transferrin
|
AU2019206731A1
(en)
|
2018-01-15 |
2020-07-30 |
Ionis Pharmaceuticals, Inc. |
Modulators of DNM2 expression
|
EP3740472A1
(de)
|
2018-01-19 |
2020-11-25 |
Synthena AG |
Tricyclo-dna-nukleosidvorläufer und verfahren zu ihrer herstellung
|
US20190233816A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
US11566236B2
(en)
|
2018-02-05 |
2023-01-31 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
US11268077B2
(en)
|
2018-02-05 |
2022-03-08 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
JP7317029B2
(ja)
|
2018-02-12 |
2023-07-28 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
修飾化合物及びその使用
|
EP3752616A1
(de)
|
2018-02-16 |
2020-12-23 |
CRISPR Therapeutics AG |
Zusammensetzungen und verfahren zur geneditierung durch targeting von fibrinogen-alpha
|
SG11202007728QA
(en)
|
2018-02-26 |
2020-09-29 |
Synthorx Inc |
Il-15 conjugates and uses thereof
|
TW202000199A
(zh)
|
2018-03-02 |
2020-01-01 |
美商Ionis製藥公司 |
Irf4 表現之調節劑
|
EP3759127A4
(de)
|
2018-03-02 |
2022-03-30 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulation des amyloid-beta-vorläuferproteins
|
CN112424348A
(zh)
|
2018-03-19 |
2021-02-26 |
克里斯珀医疗股份公司 |
新颖的rna-可编程的内切核酸酶系统及其用途
|
WO2019183440A1
(en)
|
2018-03-22 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
WO2019186514A2
(en)
|
2018-03-30 |
2019-10-03 |
Rheinische Friedrich-Wilhelms-Universitat Bonn |
Aptamers for targeted activaton of t cell-mediated immunity
|
JP2021520781A
(ja)
|
2018-04-06 |
2021-08-26 |
チルドレンズ メディカル センター コーポレーションChildren’S Medical Center Corporation |
体細胞リプログラミングおよびインプリンティングのモジュレートのための組成物および方法
|
CA3094020A1
(en)
|
2018-04-11 |
2019-10-17 |
Ionis Pharmaceuticals, Inc. |
Modulators of ezh2 expression
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
WO2019213571A1
(en)
|
2018-05-03 |
2019-11-07 |
The Trustees Of Wheaton College |
Improved membranes for nanopore sensing applications
|
AU2019266307A1
(en)
|
2018-05-09 |
2020-11-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ATXN3 expression
|
BR112020020957B1
(pt)
|
2018-05-09 |
2022-05-10 |
Ionis Pharmaceuticals, Inc |
Compostos oligoméricos, população e composição farmacêutica dos mesmos e seus usos
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
AU2019287635A1
(en)
|
2018-06-14 |
2020-12-17 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing STMN2 expression
|
SG11202011864XA
(en)
|
2018-06-27 |
2020-12-30 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing lrrk2 expression
|
WO2020023737A1
(en)
|
2018-07-25 |
2020-01-30 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn2 expression
|
TW202023574A
(zh)
|
2018-08-13 |
2020-07-01 |
美商阿尼拉製藥公司 |
B型肝炎病毒(HBV)dsRNA劑組合物及其使用方法
|
WO2020037125A1
(en)
|
2018-08-16 |
2020-02-20 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
CN113329739A
(zh)
|
2018-08-20 |
2021-08-31 |
罗贡股份有限公司 |
用于治疗scn1a脑病的靶向scn2a的反义寡核苷酸
|
CA3110661A1
(en)
|
2018-08-29 |
2020-03-05 |
University Of Massachusetts |
Inhibition of protein kinases to treat friedreich ataxia
|
EP3620520A1
(de)
|
2018-09-10 |
2020-03-11 |
Universidad del Pais Vasco |
Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
|
SG11202102531WA
(en)
|
2018-09-14 |
2021-04-29 |
Univ Northwestern |
Programming protein polymerization with dna
|
AU2019344776A1
(en)
|
2018-09-18 |
2021-01-21 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
|
TW202023573A
(zh)
|
2018-09-19 |
2020-07-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
AU2019362000A1
(en)
|
2018-10-17 |
2021-05-20 |
Bayer Healthcare Llc |
Compositions and methods for delivering transgenes
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
TW202039840A
(zh)
|
2018-11-15 |
2020-11-01 |
美商伊奧尼斯醫藥公司 |
Irf5表現調節劑
|
US20220025366A1
(en)
|
2018-11-21 |
2022-01-27 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing prion expression
|
US20210332495A1
(en)
|
2018-12-06 |
2021-10-28 |
Northwestern University |
Protein Crystal Engineering Through DNA Hybridization Interactions
|
SI3897672T1
(sl)
|
2018-12-20 |
2024-02-29 |
Humabs Biomed Sa |
Kombinirana terapija HBV
|
EP3898977A1
(de)
|
2018-12-20 |
2021-10-27 |
Praxis Precision Medicines, Inc. |
Zusammensetzungen und verfahren zur behandlung von kcnt1-assoziierten erkrankungen
|
JP2022514778A
(ja)
|
2018-12-21 |
2022-02-15 |
ノースウェスタン ユニバーシティ |
筋膜損傷の予防および治療におけるアネキシンの使用
|
WO2020139977A1
(en)
|
2018-12-26 |
2020-07-02 |
Northwestern University |
Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
|
MX2021008628A
(es)
|
2019-01-16 |
2021-11-17 |
Genzyme Corp |
Composiciones de arni para serpinc1 y metodos de uso de las mismas.
|
CA3128093A1
(en)
|
2019-01-31 |
2020-08-06 |
Ionis Pharmaceuticals, Inc. |
Modulators of yap1 expression
|
KR20210123299A
(ko)
|
2019-02-06 |
2021-10-13 |
신톡스, 인크. |
Il-2 콘쥬게이트 및 이의 사용 방법
|
AU2020221340A1
(en)
|
2019-02-15 |
2021-09-16 |
Bayer Healthcare Llc |
Gene editing for hemophilia A with improved Factor VIII expression
|
SG11202108450SA
(en)
|
2019-02-27 |
2021-09-29 |
Ionis Pharmaceuticals Inc |
Modulators of malat1 expression
|
US20220175956A1
(en)
|
2019-03-06 |
2022-06-09 |
Northwestern University |
Hairpin-like oligonucleotide-conjugated spherical nucleic acid
|
CN113924127A
(zh)
|
2019-03-11 |
2022-01-11 |
奥克斯纳健康系统公司 |
在患有自发性脑内出血的患者中作为癫痫发作的生物标志物的微rna调节网络
|
SG11202109741VA
(en)
|
2019-03-12 |
2021-10-28 |
Crispr Therapeutics Ag |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
CN117431244A
(zh)
|
2019-03-29 |
2024-01-23 |
Ionis制药公司 |
用于调节ube3a-ats的化合物和方法
|
KR20220036914A
(ko)
|
2019-05-13 |
2022-03-23 |
비르 바이오테크놀로지, 인코포레이티드 |
B형 간염 바이러스(hbv) 감염을 치료하기 위한 조성물 및 방법
|
WO2020243292A1
(en)
|
2019-05-28 |
2020-12-03 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing fus expression
|
CA3140112A1
(en)
|
2019-05-31 |
2020-12-03 |
Streck, Inc. |
Detection of antibiotic resistance genes
|
BR112021025130A2
(pt)
|
2019-06-14 |
2022-03-15 |
Scripps Research Inst |
Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos
|
WO2021021673A1
(en)
|
2019-07-26 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
JP2022544587A
(ja)
|
2019-08-15 |
2022-10-19 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
結合修飾オリゴマー化合物及びその使用
|
KR20220047598A
(ko)
|
2019-08-15 |
2022-04-18 |
신톡스, 인크. |
Il-2 콘쥬게이트를 사용한 면역 종양학 병용 요법
|
US20210054040A1
(en)
|
2019-08-23 |
2021-02-25 |
Synthorx, Inc. |
Novel il-15 conjugates and uses thereof
|
WO2021046122A1
(en)
|
2019-09-03 |
2021-03-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
KR20220061158A
(ko)
|
2019-09-10 |
2022-05-12 |
신톡스, 인크. |
자가면역질환을 치료하기 위한 il-2 접합체 및 사용 방법
|
WO2021067747A1
(en)
|
2019-10-04 |
2021-04-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
WO2021074772A1
(en)
|
2019-10-14 |
2021-04-22 |
Astrazeneca Ab |
Modulators of pnpla3 expression
|
EP4045652A1
(de)
|
2019-10-18 |
2022-08-24 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen eines elements der solute-carrier-familie und verwendungsverfahren dafür
|
BR112022007540A2
(pt)
|
2019-10-22 |
2022-07-12 |
Alnylam Pharmaceuticals Inc |
Composições de irna de componente complementar c3 e métodos de uso das mesmas
|
WO2021086623A1
(en)
|
2019-10-31 |
2021-05-06 |
The Trustees Of Wheaton College |
Design and characterization of multilayered structures for support of lipid bilayers
|
EP4051796A1
(de)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
|
CA3155921A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTINE (HTT) TARGETING RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
JP2022554272A
(ja)
|
2019-11-04 |
2022-12-28 |
シンソークス, インコーポレイテッド |
インターロイキン10コンジュゲートおよびその使用
|
CN114981431A
(zh)
|
2019-11-13 |
2022-08-30 |
阿尔尼拉姆医药品有限公司 |
用于治疗血管紧张素原(agt)相关病症的方法和组合物
|
EP4061945A1
(de)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
|
AU2020391215A1
(en)
|
2019-11-27 |
2022-06-02 |
Bayer Healthcare Llc |
Methods of synthesizing RNA molecules
|
JP2023506181A
(ja)
|
2019-12-13 |
2023-02-15 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ヒト第9染色体オープンリーディングフレーム72(C9ORF72)iRNA剤組成物およびその使用方法
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
WO2021122944A1
(en)
|
2019-12-18 |
2021-06-24 |
Alia Therapeutics Srl |
Compositions and methods for treating retinitis pigmentosa
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
US20230057461A1
(en)
|
2020-01-27 |
2023-02-23 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
EP4103714A1
(de)
|
2020-02-10 |
2022-12-21 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum unterdrücken der vegf-a expression
|
EP4107265A1
(de)
|
2020-02-18 |
2022-12-28 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein-c3 (apoc3)-irna-zusammensetzungen und verfahren zur verwendung davon
|
CR20220485A
(es)
|
2020-02-28 |
2022-11-10 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular smn2
|
EP4110830A1
(de)
|
2020-02-28 |
2023-01-04 |
Tallac Therapeutics, Inc. |
Transglutaminase-vermittelte konjugation
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
EP4114948A1
(de)
|
2020-03-06 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4121534A1
(de)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
|
JP2023519274A
(ja)
|
2020-03-26 |
2023-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
コロナウイルスiRNA組成物およびその使用方法
|
WO2021202443A2
(en)
|
2020-03-30 |
2021-10-07 |
Alnylam Pharmaceucticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
JP2023520582A
(ja)
|
2020-04-06 |
2023-05-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Myoc発現をサイレンシングするための組成物および方法
|
EP4133076A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon
|
US20230159933A1
(en)
|
2020-04-07 |
2023-05-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
EP4133077A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
|
CN115955972A
(zh)
|
2020-04-27 |
2023-04-11 |
阿尔尼拉姆医药品有限公司 |
载脂蛋白E(APOE)iRNA剂组合物及其使用方法
|
AU2021265813A1
(en)
|
2020-04-30 |
2022-11-10 |
Alnylam Pharmaceuticals, Inc. |
Complement factor B (CFB) iRNA compositions and methods of use thereof
|
CA3181546A1
(en)
|
2020-05-01 |
2021-11-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating atxn1
|
EP4150077A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
|
EP4150078A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
EP4150086A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
CA3162416C
(en)
|
2020-05-15 |
2023-07-04 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
US20230183707A1
(en)
|
2020-05-21 |
2023-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
CA3184289A1
(en)
|
2020-06-18 |
2021-12-23 |
Alnylam Pharmaceuticals, Inc. |
Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
|
KR20230042023A
(ko)
|
2020-06-24 |
2023-03-27 |
비르 바이오테크놀로지, 인코포레이티드 |
조작된 b형 간염 바이러스 중화 항체 및 이의 용도
|
AU2021296622A1
(en)
|
2020-06-25 |
2023-02-23 |
Synthorx, Inc. |
Immuno oncology combination therapy with IL-2 conjugates and anti-EGFR antibodies
|
WO2022006134A2
(en)
|
2020-06-29 |
2022-01-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating plp1
|
TW202227102A
(zh)
|
2020-09-22 |
2022-07-16 |
瑞典商阿斯特捷利康公司 |
治療脂肪肝病之方法
|
EP4217489A1
(de)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
|
US20220290136A1
(en)
|
2020-09-30 |
2022-09-15 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
EP3978608A1
(de)
|
2020-10-05 |
2022-04-06 |
SQY Therapeutics |
Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
|
WO2022076291A1
(en)
|
2020-10-05 |
2022-04-14 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
BR112023006364A2
(pt)
|
2020-10-09 |
2023-05-09 |
Synthorx Inc |
Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe
|
KR20230084204A
(ko)
|
2020-10-09 |
2023-06-12 |
신톡스, 인크. |
Il-2 콘쥬게이트를 사용한 면역 종양학 치료법
|
WO2022087041A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
WO2022087329A1
(en)
|
2020-10-23 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
EP4244355A1
(de)
|
2020-11-13 |
2023-09-20 |
Alnylam Pharmaceuticals, Inc. |
Gerinnungsfaktor-v (f5)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4136092A4
(de)
|
2020-11-18 |
2023-10-11 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulation der angiotensinogenexpression
|
US20240002853A1
(en)
|
2020-11-23 |
2024-01-04 |
Alpha Anomeric Sas |
Nucleic acid duplexes
|
EP4256053A1
(de)
|
2020-12-01 |
2023-10-11 |
Alnylam Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur hemmung der hao1 (hydroxysäureoxidase 1 (glycolatoxidase))-genexpression
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
JP2024501288A
(ja)
|
2020-12-23 |
2024-01-11 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
修飾tremの組成物及びその使用
|
EP4274896A1
(de)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4291243A1
(de)
|
2021-02-12 |
2023-12-20 |
Synthorx, Inc. |
Lungenkrebskombinationstherapie mit il-2-konjugaten und einem anti-pd-1-antikörper oder antigenbindendem fragment davon
|
KR20230146048A
(ko)
|
2021-02-12 |
2023-10-18 |
알닐람 파마슈티칼스 인코포레이티드 |
슈퍼옥사이드 디스뮤타제 1(sod1) irna 조성물 및 슈퍼옥사이드 디스뮤타제 1- (sod1-) 관련 신경퇴행성 질환을 치료하거나 예방하기 위한 이의 사용 방법
|
WO2022174101A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Skin cancer combination therapy with il-2 conjugates and cemiplimab
|
EP4298220A1
(de)
|
2021-02-25 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Prionprotein (prnp)-irna-zusammensetzungen und verfahren zur verwendung davon
|
IL305153A
(en)
|
2021-02-26 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Ketohexokinase (KHK) iRNA compositions and methods of using them
|
IL305418A
(en)
|
2021-03-04 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
WO2022192038A1
(en)
|
2021-03-12 |
2022-09-15 |
Northwestern University |
Antiviral vaccines using spherical nucleic acids
|
IL307239A
(en)
|
2021-03-29 |
2023-11-01 |
Alnylam Pharmaceuticals Inc |
Preparations containing Huntingtin IRNA factor (HTT) and methods of using them
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
WO2022214632A1
(en)
|
2021-04-07 |
2022-10-13 |
Neoplants Sas |
Compositions and methods for indoor air remediation
|
BR112023022284A2
(pt)
|
2021-04-26 |
2023-12-26 |
Alnylam Pharmaceuticals Inc |
Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma
|
EP4330396A1
(de)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4334448A1
(de)
|
2021-05-03 |
2024-03-13 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von transthyretin(ttr)-vermittelter amyloidose
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
WO2022246023A1
(en)
|
2021-05-20 |
2022-11-24 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
TW202317762A
(zh)
|
2021-06-02 |
2023-05-01 |
美商艾拉倫製藥股份有限公司 |
含有類PATATIN磷脂酶結構域3(PNPLA3)的iRNA組成物及其使用方法
|
TW202313117A
(zh)
|
2021-06-03 |
2023-04-01 |
美商欣爍克斯公司 |
包含il-2接合物及西妥昔單抗(cetuximab)之頭頸癌組合療法
|
TW202308663A
(zh)
|
2021-06-04 |
2023-03-01 |
美商艾拉倫製藥股份有限公司 |
人類染色體9開讀框72(C9ORF72)iRNA劑組成物及其使用方法
|
AR126070A1
(es)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
|
EP4101928A1
(de)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Programmierbare typ-v-rna-endonukleasesysteme
|
BR112023023768A2
(pt)
|
2021-06-11 |
2024-02-27 |
Bayer Ag |
Sistemas de endonucleases programáveis por rna tipo v
|
AU2022293556A1
(en)
|
2021-06-18 |
2024-01-18 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ifnar1 expression
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
AU2022303164A1
(en)
|
2021-06-30 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
WO2023285431A1
(en)
|
2021-07-12 |
2023-01-19 |
Alia Therapeutics Srl |
Compositions and methods for allele specific treatment of retinitis pigmentosa
|
IL309905A
(en)
|
2021-07-23 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
IRNA compositions in β-catenin (CTNNB1) and methods of using them
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
WO2023014677A1
(en)
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
TW202337474A
(zh)
|
2021-08-04 |
2023-10-01 |
美商艾拉倫製藥股份有限公司 |
用於緘默血管收縮素原(AGT)的iRNA組成物及方法
|
TW202334413A
(zh)
|
2021-08-13 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
第十二因子(F12)iRNA組成物及其使用方法
|
WO2023034870A2
(en)
|
2021-09-01 |
2023-03-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing dmpk expression
|
EP4144841A1
(de)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
WO2023044094A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023056329A1
(en)
|
2021-09-30 |
2023-04-06 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
AR127477A1
(es)
|
2021-10-29 |
2024-01-31 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi CONTRA EL FACTOR B DEL COMPLEMENTO (CFB) Y MÉTODOS DE USO DE LAS MISMAS
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
WO2023086292A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
WO2023086295A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Antisense oligonucleotides for modifying protein expression
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023118349A1
(en)
|
2021-12-21 |
2023-06-29 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023194359A1
(en)
|
2022-04-04 |
2023-10-12 |
Alia Therapeutics Srl |
Compositions and methods for treatment of usher syndrome type 2a
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024050261A1
(en)
|
2022-08-29 |
2024-03-07 |
University Of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024056880A2
(en)
|
2022-09-16 |
2024-03-21 |
Alia Therapeutics Srl |
Enqp type ii cas proteins and applications thereof
|